United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Milestone Asset Management LLC

Milestone Asset Management LLC lessened its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 76.2% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 684 shares of the biotechnology company’s stock after selling 2,190 shares during the period. Milestone Asset Management LLC’s holdings in United Therapeutics were worth $211,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Wealthfront Advisers LLC raised its stake in shares of United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock worth $6,462,018,000 after buying an additional 18,313,424 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of United Therapeutics by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company’s stock worth $1,567,253,000 after buying an additional 32,213 shares during the last quarter. FMR LLC raised its stake in shares of United Therapeutics by 36.5% during the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock worth $519,170,000 after buying an additional 393,777 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of United Therapeutics by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company’s stock worth $401,184,000 after buying an additional 44,277 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of United Therapeutics by 0.8% during the 4th quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company’s stock worth $344,176,000 after buying an additional 7,710 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In other United Therapeutics news, Director Raymond Dwek sold 3,000 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $285.57, for a total value of $856,710.00. Following the completion of the sale, the director now owns 1,750 shares of the company’s stock, valued at $499,747.50. This trade represents a 63.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $316.07, for a total value of $3,476,770.00. Following the transaction, the executive vice president now owns 36,781 shares of the company’s stock, valued at approximately $11,625,370.67. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,500 shares of company stock valued at $16,923,950. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

NASDAQ UTHR opened at $325.48 on Tuesday. United Therapeutics Co. has a 12 month low of $266.98 and a 12 month high of $417.82. The company has a 50-day moving average of $299.78 and a 200-day moving average of $334.24. The company has a market cap of $14.68 billion, a P/E ratio of 14.29, a P/E/G ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts’ consensus estimates of $6.29 by $0.34. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.17 EPS. As a group, equities research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Bank of America raised United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 price target for the company in a research note on Monday, April 21st. Wells Fargo & Company reissued an “equal weight” rating and issued a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Wall Street Zen downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. Cantor Fitzgerald initiated coverage on shares of United Therapeutics in a research note on Monday. They issued an “overweight” rating and a $405.00 target price for the company. Finally, Morgan Stanley boosted their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a research note on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $393.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.